Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT01743859

Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

The primary objective of this study is to determine the complete remission/complete remission with incomplete recovery of blood counts (CR/CRi) rate for relapsed and refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) patients.

Status: 
Recruiting
Study Date: 
Sat, 12/01/2012 to Tue, 11/01/2016
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Associated Drug(s): 
Intervention: 
Drug: Azacitidine Enrolled patients will receive 75 mg/m2 of azacitidine subcutaneously (SC) or intravenously (IV) on days 1-7 alone. Other Name: Vidaza (TM) Drug: Lenalidomide Beginning on day 8, patients will receive 50 mg of lenalidomide PO, and will take this daily from day 8 through 28. Other Name: Revlimid (TM) Other: Off Therapy 2 weeks off therapy, then begin sequence again for 12 weeks. Study Arm (s) Experimental: Azacitidine